Norgine
Tracked across 5 events · 32 articles · First seen Apr 07, 2026 · Last active Jun 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Norgine received TGA registration for PEDMARQSI in Australia, expanding its market reach for this specialized medicine.
May 05, 2026 · 6 articles
Business
Impact: Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI in Europe, U.K., Australia, and New Zealand.
May 07, 2026 · 6 articles
Business
Impact: Norgine is the exclusive licensing partner for Fennec Pharmaceuticals' product PEDMARQSI in Europe, the UK, Australia, and New Zealand, contributing to the global commercialization of the drug.
May 14, 2026 · 6 articles
Business
Impact: Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI (PEDMARK) in Europe, U.K., Australia, and New Zealand.
Apr 07, 2026 · 7 articles
Business
Impact: Norgine is mentioned as a commercialization partner for PEDMARQSI, providing context on Fennec Pharmaceuticals' broader business activities, though not directly impacted by this specific stock option grant.
May 18, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Norgine live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard